In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - Neurokinin 1 receptor antagonist chimera

Molecular Brain

Volumn 5, Issue 1, 2012, Pages

  Guillemyn, Karel ^a   Kleczkowska, Patrycja ^b   Novoa, Alexandre ^a   Vandormael, Bart ^a   Van Den Eynde, Isabelle ^a   Kosson, Piotr ^b   Asim, Muhammad ^c   Schiller, Peter W ^d   Spetea, Mariana ^c   Lipkowski, Andrzej W ^b   Tourwé, Dirk ^a   Ballet, Steven ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

dual opioid agonist neurokinin antagonist peptidomimetic; Opioid tetrapeptides; tolerance studies

Indexed keywords

BENZAZEPINE DERIVATIVE; DELTA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NEUROKININ 1 RECEPTOR ANTAGONIST; TETRAPEPTIDE; ANALGESIC AGENT; LIGAND; NEUROKININ 1 RECEPTOR; OLIGOPEPTIDE; OPIATE PEPTIDE; RECOMBINANT PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG TOLERANCE; IN VIVO STUDY; LIPOPHILICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL FLICK TEST; ANIMAL; C57BL MOUSE; CHEMISTRY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NOCICEPTION; TIME;

ANIMALIA;

ANALGESICS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENOUS; LIGANDS; MICE; MICE, INBRED C57BL; MORPHINE; NOCICEPTION; OLIGOPEPTIDES; OPIOID PEPTIDES; RECEPTORS, NEUROKININ-1; RECEPTORS, OPIOID, MU; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 84856253746     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-5-4     Document Type: Article

References (49)

1. International Union of Pharmacology. XIII. Classification of Opioid Receptors. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M, Pharmacol Rev 1996 48 567 592 (Pubitemid 27023821)
2. Opioid receptors. McDonald J, Lambert DG, Contin Educ Anaesth Crit Care Pain 2005 5 22 25 (Pubitemid 41219045)
3. Opioid complications and side effects. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R, Pain Physician 2008 11 105 S120
4. Management of common opioid-induced adverse-effects. Swegle JM, Logemann C, Am Fam Phisician 2006 74 1347 1354
5. Opioid ligands with mixed / opioid receptor interactions: an emerging approach to novel analgesics. Ananthan S, AAPS J 2006 8 118 E125
6. Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity. Horan P, Tallarida RJ, Haaseth RC, Matsunaga TO, Hruby VJ, Porreca F, Life Sci 1992 50 1535 1541
7. Differential effects of leucine and methionine enlephalin on morphine-induced analgesia, acute tolerance and dependence. Vaught JL, Takemori AE, J Pharmacol Exp Ther 1979 208 86 90 (Pubitemid 9154079)
8. Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE, J Pharmacol Exp Ther 1991 258 299 303
9. Simultaneous targeting of multiple opioid receptors: a strategy to improve side- effect profile. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG, Br J Anaesth 2009 103 38 49
10. CNS Drug Delivery: Opioid Peptides and the Blood-Brain Barrier. Witt KA, Davis TP, AAPS Journal 2006 8 76 E88
11. Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. Egleton RD, Mitchell SA, Huber JD, Palian MM, Polt R, Davis TP, J Pharmacol Ex Ther 2001 299 967 972 (Pubitemid 33104967)
12. Lipid, sugar and liposaccharide based delivery systems 2. Blanchfield J, Toth I, Curr Med Chem 2004 11 2375 2382 (Pubitemid 39172355)
13. Optimizing oral absorption of peptides using prodrug strategies. Borchardt RT, J Control Release 1999 62 231 238 (Pubitemid 29486502)
14. New trends in the development of opioid peptide analogues as advanced remedies for pain relief. Gentilucci L, Curr Topics Med Chem 2004 4 19 38 (Pubitemid 38842559)
15. Whole body and brain distribution of [3H]cyclic [d-Pen2,d-Pen5] enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration. Weber SJ, Greene DL, Hruby VJ, Yamamura HI, Porreca F, Davis TP, J Pharmacol Exp Ther 1992 263 1308 1316 (Pubitemid 23157213)
16. Designed multiple ligands: an emerging drug discovery paradigm. Morphy R, Rankovic Z, J Med Chem 2005 48 6523 6543 (Pubitemid 41504710)
17. Design of Multitarget Ligands. Morphy R, Rankovic Z, Lead Generation Approaches in Drug Discovery Hoboken: John Wiley & Sons, Inc. 2010 141 164
18. Bi- or multifunctional opioid peptide drugs. Schiller PW, Life Sci 2010 86 598 603
19. Codrug: an efficient approach for drug optimization. Das N, Dhanawat M, Dash B, Nagarwal NC, Shrivastava SK, Eur J Pharmacol Sci 2010 41 571 588
20. A novel chemical delivery system comprising an ocular sustained release formulation of a 3, 17, 21-trihydroxy-5- pregnan-20-one-BIS-5-Flouroucil codrug. Howard M, Al-Ghananeem A, Crooks PA, Drug Dev Ind Pharm 2007 33 677 682 (Pubitemid 47035885)
21. Spinal antinociceptive effects of AA501, a novel chimeric peptide wit opioid receptor agonist and tachykinin receptor antagonist moieties. Boney IM, Foran SE, Marchand JE, Lipkowski AW, Carr DB, Eur J Pharmacol 2004 488 91 99 (Pubitemid 38388528)
22. Novel bifunctional peptides as opioid agonists and NK-1 antagonists. Nair P, Yamamoto T, Kulkarni V, Moye S, Navratilova E, Davis P, Largent T, Ma S-W, Yamamura HI, Vanderah TW, Lai J, Porreca F, Hruby VJ, Adv Exp Med Biol 2009 611 537 538
23. The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety. Yamamoto T, Nair P, Ma S-W, Davis P, Yamamura HI, Vanderah TW, Porreca F, Lai J, Hruby VJ, Bioorg Med Chem 2009 17 7337 7343
24. Discovery of a potent and efficacious peptide derivative for / opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: In vitro, in vivo, and NMR-based structural studies. Yamamoto T, Nair P, Largent-Milnes TM, Jacobsen NE, Davis P, Ma S-W, Yamamura HI, Vanderah TW, Porreca F, Lai J, Hruby VJ, J Med Chem 2011 54 2029 2038
25. Substance P and related tachikinins. Rupniak NMJ, Kramer R, Neuropharmacology The fifth generation of progress Philadelphia: Lippincott Williams & Wilkins, Davis KL, Charney D, Coyle JT et al, 2002 169 178
26. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. King T, Gardell LR, Wang R, Vardanyan A, Ossipov MH, Malan TP Jr, Vanderah TW, Hunt SP, Hruby VJ, Lai J, Porreca F, Pain 2005 116 276 288 (Pubitemid 40957131)
27. Is paradoxical pain induced by sustained opioid exposure and underlying mechanism of opioid antinociceptive tolerance? King T, Ossipov MH, Vanderah TW, Porreca F, Lai J, Neurosignals 2005 14 194 205 (Pubitemid 41417108)
28. The Dermorphin Peptide Family. Melchiorri P, Negri L, Gen Pharmac 1996 27 1099 1107 (Pubitemid 26375421)
29. Production of antinociception by peripheral administration of [Lys7]Dermorphin, a naturally occurring peptide with high affinity for m-opioid receptors. Negri L, Lattanzi R, Melchiorri P, Br J Pharmacol 1995 114 57 66
30. Dermorphins are naturally opioids with an unique primary structure that determines their biological specificity. Usenko AB, Emel'yanowa TG, Myasoedov NF, Biol Bull 2002 29 154 164 (Pubitemid 34281189)
31. 1]Dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed / opioid receptor agonistic properties. Vandormael B, Fourla D-D, Gramowski-Vo A, Kosson P, Weiss DG, Schröder OH-U, Lipkowski AW, Georgoussi Z, Tourwé D, J Med Chem 2011 54 7848 7859
32. Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist. Ballet S, Feytens D, Buysse K, Chung NN, Lemieux C, Tumati S, Keresztes A, Van Duppen J, Lai J, Varga E, Porreca F, Schiller PW, Vanden Broeck J, Tourwé D, J Med Chem 2011 54 2467 2476
33. 5]enkephalin. Hansen DW Jr, Stapelfeld A, Savage MA, Reichman M, Hammond DL, Haaseth RC, Mosberg HI, J Med Chem 1992 35 684 687
34. Synthesis and biological evaluation of constrained analogues of the opioid peptide H-Tyr-D-Ala-Phe-Gly-NH2 using 4-amino-2-benzazepin-3-one scaffold. Ballet S, Frycia A, Piron J, Chung NN, Schiller PW, Kosson P, Lipkowski AW, Tourwé D, J Peptide Res 2005 66 222 230 (Pubitemid 41564310)
35. Conformational restriction of Tyr and Phe side-chain in opioid peptides: Information about preferred and bioactive side-chain topology. Tourwé D, Verschueren K, Frycia A, Davis P, Porreca F, Hruby VJ, Toth G, Jaspers H, Verheyden P, Van Binst G, Biopolymers 1996 38 1 12
36. Dermorphin sequence with high delta-affinity by fixing the Phe side-chain to trans at alpha-1. Tourwé D, Verschueren K, Van Binst G, Davis P, Porreca F, Hruby VJ, Bioorg Med Chem Lett 1992 2 1305 1308
37. PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects. Kleczkowska P, Kosson P, Ballet S, Van den Eynde I, Tsuda Y, Tourwé D, Lipkowski AW, Mol Pain 2010 6 86 92
38. Statistical primer for cardiovascular research. Analysis of variance. Larson MG, Circulation 2008 117 115 121
39. Significantly different: using inferential statistics. Statistics for people who (think they) hate statistics SAGE Publications, Inc., Salkind NJ, 2010 221 238
40. Spinal co-administration of peptide substance P antagonist increases antinociceptive effect of the opioid peptide biphalin. Misterek K, Maszczynska I, Dorociak A, Gumulka SW, Carr DB, Szyfelbein SK, Lipkowski AW, Life Sci 1994 54 939 944 (Pubitemid 24110157)
41. Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines. Yamamoto T, Nair P, Jacobsen NE, Kulkarni V, Davis P, Ma S-W, Navratilova E, Yamamura HI, Vanderah TW, Porreca F, Lai J, Hruby VJ, J Med Chem 2010 53 5491 5501
42. Synthesis and in vitro opioid activity profiles of DALDA analogues. Schiller PW, Nguyen TMD, Berezowska I, Dupuis S, Weltrowska G, Chung NN, Lemieux C, Eur J Med Chem 2000 35 895 901
43. Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. Largent-Milnes TM, Yamamoto T, Nair P, Moulton JW, Hruby VJ, Lai J, Porreca F, Vanderah TW, Br J Pharmacol 2010 161 986 1001
44. Alternative forms of interaction of substance P and opioids in nociceptive transmission. Maszczynska I, Lipkowski AW, Carr DB, Kream RM, Lett Pept Sci 1998 5 395 398 (Pubitemid 128511626)
45. Testing and evaluation of opiate analgesics and antagonists. Hahn EF, Methods Find Exp Clin Pharmacol 1985 7 373 381 (Pubitemid 15242851)
46. A method for determining loss of pain sensation. D'Amour FE, Smith DL, J Pharmacol Exp Ther 1941 72 74 79
47. pA2, a new scale for the measurement of drug antagonism. Schild HO, Br J Pharmacol 1947 2 189 206
48. Regulation of spontaneous activity of delta-opioid receptor: studies of inverse agonism in intact cells. Merkouris M, Mullaney I, Georgoussi Z, Milligan G, J Neurochem 1997 69 2115 2122 (Pubitemid 27452759)
49. Synthesis amd pharmacological characterization in vitro of cyclic enkephalin analogues: effect of the conformational constraints on opioid receptor selectivity. DiMaio J, Nguyen TMD, Lemieux C, Schiller PW, J Med Chem 1982 25 1432 1438 (Pubitemid 13212471)